Therapeutic Advances in Diabetic Nephropathy.
Hanny SawafGeorge ThomasJonathan J TaliercioGeorges NakhoulTushar J VachharajaniAli MehdiPublished in: Journal of clinical medicine (2022)
Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin-angiotensin-aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease.
Keyphrases
- blood glucose
- diabetic nephropathy
- blood pressure
- type diabetes
- angiotensin converting enzyme
- angiotensin ii
- glycemic control
- wound healing
- risk factors
- blood brain barrier
- small molecule
- high fat diet
- computed tomography
- protein protein
- contrast enhanced
- magnetic resonance imaging
- metabolic syndrome
- insulin resistance
- amino acid
- adipose tissue
- weight loss
- skeletal muscle